Digoxin Therapy of Fetal Superior Ventricular Tachycardia: Are Digoxin Serum Levels Reliable?

Abstract

Background Despite its seldom occurrence, fetal tachycardia can lead to poor fetal outcomes including hydrops and fetal death. Management can be challenging and result in maternal adverse effects secondary to high serum drug levels required to achieve effective transplacental antiarrhythmic drug therapy.

Case A 33-year-old woman at 33 weeks of gestation with a diagnosis of a fetal sustained superior ventricular tachycardia developed chest pain, shortness of breath, and bigeminy on electrocardiogram secondary to digoxin toxicity despite subtherapeutic serum drug levels. She required supportive care with repletion of corresponding electrolyte abnormalities. After resolution of cardiac manifestations of digoxin toxicity, the patient was discharged home. The newborn was discharged at day 9 of life on maintenance amiodarone.

Conclusion We describe an interesting case of digoxin toxicity with cardiac manifestations of digoxin toxicity despite subtherapeutic serum drug levels. This case report emphasizes the significance of instituting an early diagnosis of digoxin toxicity during pregnancy, based not only on serum drug levels but also on clinical presentation. In cases of refractory supportive care, digoxin Fab fragment antibody administration should be considered. With timely diagnosis and treatment, excellent maternal and perinatal outcomes can be achieved.

Keywords

pregnancy - fetal SVT - digoxin - toxicity

• References

• 1 Owen P, Cameron A. Fetal tachyarrhythmias. Br J Hosp Med 1997; 58 (4) 142-144
• 2 Vergani P, Mariani E, Ciriello E , et al. Fetal arrhythmias: natural history and management. Ultrasound Med Biol 2005; 31 (1) 1-6
• 3 Jaeggi E. Electrophysiology for the perinatologist. In: Yagel S, Silverman NH, Gembruch U, eds. Fetal Cardiology, 2nd ed. New York: Informa Healthcare London; 2009: 435-447
• 4 Jaeggi E, Tulzer G. Pharmacological and interventional fetal cardiovascular treatment. In: Anderson RH, Baker EJ, Redington A, et al, eds. Paediatric Cardiology. 3rd ed. Philadelphia: Elsevier; 2009: 199
• 5 Donofrio MT, Moon-Grady AJ, Hornberger LK , et al; American Heart Association Adults With Congenital Heart Disease Joint Committee of the Council on Cardiovascular Disease in the Young and Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Council on Cardiovascular and Stroke Nursing. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association. Circulation 2014; 129 (21) 2183-2242
• 6 Smith TW, Antman EM, Friedman PL, Blatt CM, Marsh JD. Digitalis glycosides: mechanisms and manifestations of toxicity. Part I. Prog Cardiovasc Dis 1984; 26 (5) 413-458
• 7 Lewander WJ, Gaudreault P, Einhorn A, Henretig FM, Lacouture PG, Lovejoy Jr FH. Acute pediatric digoxin ingestion. A ten-year experience. Am J Dis Child 1986; 140 (8) 770-773
• 8 Graves SW, Brown B, Valdes Jr R. An endogenous digoxin-like substance in patients with renal impairment. Ann Intern Med 1983; 99 (5) 604-608
• 9 Bayer MJ. Recognition and management of digitalis intoxication: implications for emergency medicine. Am J Emerg Med 1991; 9 (2) (Suppl. 01) 29-32 , discussion 33–34